Loading...
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria
BACKGROUND: Eculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains a high treatment burden. Ravulizumab administered every 8 weeks demonstrated noninferiority to eculizumab in two phase 3 trials. In regions...
Na minha lista:
| Udgivet i: | PLoS One |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Public Library of Science
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7473546/ https://ncbi.nlm.nih.gov/pubmed/32886668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0237497 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|